BioNxt Solutions, Morphosys, Palantir - Innovative therapies for Parkinson's, cancer and soaring with AI

BioNxt Solutions: Develops innovative approach to alleviating Parkinson's disease

There is a lot going on in the biotech sector right now. Investors know that medical research, in particular, requires staying power. Thanks to innovative AI technologies, companies are already able to analyze and evaluate data faster and more efficiently. BioNxt Solutions bionxt.com/investors is developing an innovative medical patch which will enable Parkinson's patients to enjoy symptom relief more quickly. What many readers overlook is that the skin is our largest organ, and active substances absorbed through the skin reach the bloodstream faster than any pill.

Parkinson's disease often manifests as uncontrollable trembling of one hand and stiffness of the body. As it progresses, other symptoms may include slurred speech, a sluggish gait, loss of the sense of smell, and dementia. Men are 50% more likely to develop PD than women, and in most cases, symptoms appear at age 60 or older.

The drug for the current standard of care for Parkinson's was discovered 66 years ago. To date, Parkinson's cannot be cured; only its symptoms can be alleviated. Reason enough for BioNxt Solutions to do valuable pioneering work in this area.

The patch carries the active ingredient rotigotine, which is approved for treating Parkinson's disease and restless legs syndrome (RLS) in Europe and the US. As a patch, it is applied once daily to ensure controlled, consistent drug delivery over 24 hours. According to Wissen Market Research, total global sales of rotigotine patches were approximately EUR 462.7 million in 2021, and the market is expected to exceed EUR 684.3 million by 2030.

Morphosys: On track for blockbuster drug in the fight against cancer

The German-American biotech company Morphosys is confident about its drug Pelabresib for the treatment of a rare form of blood cancer. Blood cancers arise in blood-forming tissues such as bone marrow or immune system cells. Leukaemia, lymphoma and multiple myeloma are examples of blood cancers. Company CEO Jean-Paul Kress expressed optimism to the "Frankfurter Allgemeine Zeitung" and is convinced that blockbuster status can be achieved with this. In the pharmaceutical industry, blockbuster drugs are those that generate sales of more than USD 1 billion (EUR 893 million) per year. Results from the Phase III trial are expected at the end of this year, six months ahead of schedule because patients were recruited more quickly.

According to a study by Bristol Myers Squibb, approximately 1.85 million new blood cancer cases are expected worldwide in 2040. Lymphoma accounts for 918,872 cases, leukaemia 656,345 cases, and myeloma 275,047 cases. The study also predicts approximately 1,100,000 deaths worldwide due to blood cancers by 2040. Morphosys' therapeutic agent targets the cancer condition Myelofibrosis.

Myelofibrosis is a disease in which blood-forming cells in the bone marrow are overgrown by connective tissue, resulting in abnormally shaped red blood cells, anaemia and an enlarged spleen. This disease can occur independently, through certain gene mutations, or due to other blood disorders. Morphosys is conducting research on Pelabresib (CPI-0610). It is a development-stage compound. It aims to promote anti-tumor activity by inhibiting the function of certain proteins to reduce the outgrowth of abnormally expressed genes in cancer.

Deutsche Bank analysts rated the stock a "hold. " In his research note, analyst Emmanuel Papadakis highlighted the importance of myelofibrosis to the European pharmaceutical industry and the opportunities for Morphosys' drug Pelabresib, which is currently in a pivotal trial phase against the malignant bone marrow disease. Data on this is expected in the fourth quarter. Traders rewarded that assessment, sending the stock soaring 4.9% this week.

Palantir: Enters drone technology in Canadian airspace

Palantir Technologies and Canadian company AirMatrix, a pioneer in airspace infrastructure technology, have announced a strategic partnership to accelerate and scale drone operations by leveraging Palantir Foundry through the Foundry for Builders Program. AirMatrix is harnessing the potential of urban aviation and working on technology that will enable autonomous commercial drone operations worldwide.

AirMatrix's main products are "Palladium UTM" and Libra. Palladium UTM is designed specifically for corporate drone pilots and fleet managers. It enables them to apply for airspace permits, manage their fleet, and focus entirely on flying. Libra is a sophisticated airspace management platform enabling civil authorities to scale and manage drone traffic effectively. At the same time, it provides the opportunity to generate revenue as commercial drones take to the skies.

AirMatrix joins several other Canadian companies working with Palantir - from energy to financial services to manufacturing. As part of the Foundry for Builders Program, AirMatrix has begun enhancing its two commercial drone software products, Libra and Palladium.

"Drone technology is increasingly being used not only for beneficial applications but also for nefarious or illegal purposes," said David MacNaughton, Director & Head of Palantir Technologies Canada. "Palantir Canada is pleased to support AirMatrix in accelerating and scaling our business and securing our airspace with local technical expertise."

For investors, it is good to know that Palantir results for Q2/23, which ended June 30, 2023, will be released on Monday, August 7, 2023, after the close of the US market.

Life-threatening diseases require innovative research and technologies to give sufferers back the quality of life they deserve. BioNxt Solutions, a promising biotech company, is stepping up to shake up the Parkinson's therapy market after 66 years of stagnation. With their innovative patch, patients benefit from rapid drug absorption through the skin in a growing market. According to Research and Markets, the global transdermal skin patch market was worth nearly USD 6.5 billion in 2020, while Kuick Research, Pharmaceutical and Healthcare, estimates the market will reach about USD 20 billion by 2028. Morphosys, for its part, is focused on fighting blood cancer and has a blockbuster-level drug candidate in the pipeline. The future drug is designed to inhibit tumor growth. Initial research results make the CEO optimistic. In the future, Canadian airspace will also become safer thanks to Palantir and the company AirMatrix. Both are working hand in hand on drone technology for surveillance.